Critical Reviews in Oncology / Hematology
Volume 76, Issue 3 , Pages 186-195 , December 2010

Tomorrow's targeted therapies in breast cancer patients: What is the risk for increased radiation-induced cardiac toxicity?

  • Nicolas Magné

      Affiliations

    • Department of Medical Oncology, Hôpital Pitié Salpêtrière, Paris, France
    • These authors contributed equally to this work.
    • Corresponding Author InformationCorresponding author.
    • ,
  • Cyrus Chargari

      Affiliations

    • These authors contributed equally to this work.
    • Department of Medical and Radiation Oncology, Hôpital d’Instruction des Armées du Val-de-Grâce, Paris, France
    • ,
  • Dhara MacDermed

      Affiliations

    • Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL, USA
    • ,
  • Rosa Conforti

      Affiliations

    • Department of Medical Oncology, Hôpital Pitié Salpêtrière, Paris, France
    • ,
  • Lionel Védrine

      Affiliations

    • Department of Medical and Radiation Oncology, Hôpital d’Instruction des Armées du Val-de-Grâce, Paris, France
    • ,
  • Jean-Philippe Spano

      Affiliations

    • Department of Medical Oncology, Hôpital Pitié Salpêtrière, Paris, France
    • ,
  • David Khayat

      Affiliations

    • Department of Medical Oncology, Hôpital Pitié Salpêtrière, Paris, France

,Accepted 15 January 2010.

References 

  1. Senan S, Smit EF. Design of clinical trials of radiation combined with antiangiogenic therapy. Oncologist. 2007;12:465–477
  2. Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol. 2004;22:322–329
  3. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792
  4. Coussens L, Yang-Feng TL, Liao YC, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with new oncogene. Science. 1985;230:1132–1139
  5. Ewer MS, Gibbs HR, Swafford J, Benjamin RS. Cardiotoxicity in patients receiving trastuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact?. Semin Oncol. 1999;26:96–101
  6. Crone SA, Zhao YY, Fan L, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med. 2002;8:459–465
  7. Lemmens K, Doggen K, De Keulenaer GW. Role of neuregulin-1/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure. Circulation. 2007;116:954–960
  8. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20:1215–1221
  9. Byhardi R, Brace K, Ruckdeschel J, Chang P, Martin R. Dose and treatment factors in radiation-related pericardial effusion associated with the mantle technique for Hodgkin's disease. Cancer. 1975;35:795–802
  10. Cohn KE, Stewart JR, Fejardo LF, Hancock EW. Heart disease following radiation. Medicine. 1967;46:281–298
  11. McRaynoids RA, Gold GL, Roberts WC. Coronary heart disease after mediastinal irradiation for Hodgkin's disease. Am J Med. 1976;60:39–45
  12. Host H, Brennhovd I, Leob M. Post operative radiotherapy in breast cancer—long-term results from the Oslo study. Int J Radiat Oncol Biol Phys. 1986;12:727–732
  13. Broslus FC, Waller BF, Roberts WC. Radiation heart disease. Analysis of 16 young necropsy patients who received over 3500 rads to the heart. Am J Med. 1981;70:519–530
  14. Dollinger MR, Lavine DM, Foye LV. Myocardial infarction due to postirritarion fibrosis of the coronary arteries. JAMA. 1996;195:316–319
  15. Paszat LF, Mackillop WJ, Groome PA, et al. Mortality from myocardial infarction following postlumpectomy radiotherapy for breast cancer: a population-based study in Ontario, Canada. Int J Radiat Oncol Biol Phys. 1999;43:755–762
  16. Hooning MJ, Aleman BM, van Rosmalen AJM, et al. Cause-specific mortality in long term survivors of breast cancer: a 25-year follow-up study. Int J Radiat Oncol Biol Phys. 2006;64:1081–1091
  17. Rutqvist LE, Liedberg A, Hammar N, et al. Myocardial infarction among women with early-stage breast cancer treated with conservative surgery and breast irradiation. Int J Radiat Oncol Biol Phys. 1998;40:359–363
  18. Gyenes G, Rutqvist LE, Liedberg , et al. Long-term cardiac mortality in a randomized trial of pre- and post-operation radiation therapy versus surgery alone in primary breast cancer. Radiother Oncol. 1998;48:185–190
  19. Gagliardi G, Lax I, Söderström S, et al. Prediction of excess risk of long-term cardiac mortality after radiotherapy of stage I breast cancer. Radiother Oncol. 1998;46:63–71
  20. Højris I, Overgaard M, Christensen JJ, et al. Morbidity and mortality of ischemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomized trials. Lancet. 1999;354:1425–1430
  21. Rutqvist LE, Johansson H. Mortality by laterality of the primary tumor among 55,000 breast cancer patients from the Swedish Cancer Registry. Br J Cancer. 1990;61:866–868
  22. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087–2106
  23. Roychoudhuri R, Robinson D, Putcha V, et al. Increased cardiovascular mortality more than fifteen years after radiotherapy for breast cancer: a population-based study. BMC Cancer. 2007;15:7–9
  24. Early Breast Cancer Trialists’ Collaborative Group. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet. 2000;355:1570–1757
  25. Fukutome M, Maebayashi K, Nasu S, Seki K, Mitsuhashi N. Enhancement of radiosensitivity by dual inhibition of the HER family with ZD1839 (“Iressa”) and trastuzumab (“Herceptin”). Int J Radiat Oncol Biol Phys. 2006;66:528–536
  26. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–1684
  27. Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008;26:1231–1238
  28. Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005;23:7811–7819
  29. Slamon DJ, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2-positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat. 2005;94:5;[abstract]
  30. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–1672
  31. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354:809–820
  32. Spielmann M, Roché H, Delozier T, et al. Safety analysis from PACS 04-A phase III trial comparing 6 cycles of FEC100 with 6 cycles of ET75 for node-positive early breast cancer patients, followed by sequential trastuzumab in HER2+patients: preliminary results. J Clin Oncol 2006 ASCO Annu Meet Proc Part I. 2006;24:632;[abstract]
  33. Halyard MY, Pisansky TM, Dueck AC, et al. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol. 2009;27:2638–2644
  34. Shaffer R, Tyldesley S, Rolles M, Chia S, Mohamed I. Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: a retrospective single-institution study. Radiother Oncol. 2009;90:122–126
  35. Belkacémi Y, Gligorov J, Ozsahin M, et al. Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study. Ann Oncol. 2008;19:1110–1116
  36. Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat. 2008;112:533–543
  37. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733–2743
  38. Gomez HL, Doyal DC, Chavez MA, et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol. 2008;26:2999–3005
  39. Lin NU, Carey LA, Liu MC, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2008;26:1993–1999
  40. Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc. 2008;83:679–686
  41. Moy B, Goss PE. Lapatinib-associated toxicity and practical management recommendations. Oncologist. 2007;12:756–765
  42. Ramaswamy B, Shapiro CL. Phase II trial of bevacizumab in combination with docetaxel in women with advanced breast cancer. Clin Breast Cancer. 2003;4:292–294
  43. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005;23:792–799
  44. Burstein HJ, Parker LM, Savoie J, et al. Phase II trial of the anti-VEGF antibody bevacizumab in combination with vinorelbine for refractory advanced breast cancer. Breast Cancer Res Treat. 2002;446;[abstract]
  45. Torrisi R, Bagnardi V, Cardillo A, et al. Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity. Br J Cancer. 2008;99:1564–1571
  46. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666–2676
  47. D’Adamo DR, Anderson SE, Albritton K, et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol. 2005;23:7135–7142
  48. Veronese ML, Mosenkis A, Flaherty KT, et al. Mechanisms of hypertension associated with BAY 43-9006 treatment. J Clin Oncol. 2006;24:1363–1369
  49. Mir O, Mouthon L, Alexandre J, et al. Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome?. J Natl Cancer Inst. 2007;99:85–86
  50. Mourad JJ, des Guetz G, Debbabi H, Levy BI. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol. 2008;19:927–934
  51. Hoang T, Huang S, Armstrong E, Harari PM. Augmentation of radiation response by bevacizumab (Avastin®): influence of treatment sequencing. Proc Am Assoc Cancer Res. 2005;46:546;[abstract]
  52. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 2005;65:671–680
  53. Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 1999;59:3374–3378
  54. Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008;26:5204–5212
  55. Dal Lago L, D’Hondt V, Awada A. Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. Oncologist. 2008;13:845–858
  56. Odabaei G, Chatterjee D, Jazirehi AR, et al. Raf-1 kinase inhibitor protein: Structure, function, regulation of cell signaling, and pivotal role in apoptosis. Adv Cancer Res. 2004;91:169–200
  57. Abrams TJ, Murray LJ, Pesenti E, et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast cancer. Mol Cancer Ther. 2003;2:1011–1021
  58. Burstein HJ, Elias AD, Rugo HS, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008;26:1810–1816
  59. Awada A, Hendlisz A, Whenham N, et al. Phase I trial to evaluate safety, pharmacokinetics, and efficacy of sorafenib combined with docetaxel in patients with advanced, refractory solid tumors. Ann Oncol. 2007;18:401;[abstract]
  60. T00217399: sorafenib and anastrozole in treating postmenopausal women with metastatic breast cancer. Available at http://clinicaltrials gov/ct2/results?term_NCT00217399, 2009.
  61. Khakoo AY, Kassiotis CM, Tannir N, et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer. 2008;112:2500–2508
  62. Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer. 2007;7:332–344
  63. Parisi Q, Biondi-Zoccai GG, Abbate A, et al. Hypoxia inducible factor-1 expression mediates myocardial response to ischemia late after acute myocardial infarction. Int J Cardiol. 2005;99:337–339
  64. Kido M, Du L, Sullivan CC, et al. Hypoxiainducible factor 1-reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse. J Am Coll Cardiol. 2005;46:2116–2124
  65. Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370:2011–2019
  66. Shiojima I, Sato K, Izumiya Y, et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest. 2005;115:2108–2118
  67. Motzer RJ, Hutson TE, Tomczak P, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. J Clin Oncol. 2009;27:3584–3590
  68. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–134
  69. Telli ML, Witteles RM, Fisher GA, Srinivas S. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol. 2008;19:1613–1618
  70. Hutson TE, Figlin RA, Kuhn JG, Motzer RJ. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist. 2008;13:1084–1096
  71. Magné N, Védrine L, Chargari C. Impact on cardiac toxicity with trastuzumab and radiotherapy: the question is still ongoing. J Clin Oncol. 2009;27:239
  72. Myrehaug S, Pintilie M, Tsang R, et al. Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma. 2008;49:1486–1493
  73. Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol. 2005;23:8597–8605
  74. Mouridsen H, Keshaviah A, Coates AS, et al. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of big 1–98 trial. J Clin Oncol. 2007;25:1–16
  75. Pedersen AN, Korreman S, Nyström H, et al. Breathing adapted radiotherapy of breast cancer: reduction of cardiac and pulmonary doses using voluntary inspiration breath-hold. Radiother Oncol. 2004;72:53–60
  76. Hurkmans CW, Cho BC, Damen E, et al. Reduction of cardiac and lung complication probabilities after breast irradiation using conformal radiotherapy with or without intensity modulation. Radiother Oncol. 2002;62:163–171
  77. Taylor CW, Povall JM, McGale P, et al. Cardiac doses from tangential breast cancer radiotherapy in the year 2006. Int J Radiat Oncol Biol Phys. 2008;72:501–507
  78. Gagliardi G, Lax I, Ottolenghi A, Rutqvist LE. Long-term cardiac mortality after radiotherapy of breast cancer—application of the relative seriality model. Br J Radiol. 1996;69:839–846
  79. Lohr F, El-Haddad M, Dobler B, et al. Potential effect of robust and simple IMRT approach for left-sided breast cancer on cardiac mortality. Int J Radiat Oncol Biol Phys. 2009;74:73–80
  80. Caudrelier JM, Morgan SC, Montgomery L, Lacelle M, Nyiri B, Macpherson M. Helical Tomotherapy for locoregional irradiation including the internal mammary chain in left-sided breast cancer: dosimetric evaluation. Radiother Oncol. 2009;90:99–105
  81. Korreman SS, Pedersen AN, Josipović M, et al. Cardiac and pulmonary complication probabilities for breast cancer patients after routine end-inspiration gated radiotherapy. Radiother Oncol. 2006;80:257–262
  82. Ewer MS, Perez EA, Baselga J, et al. Cardiac safety guidelines for the adjuvant use of trastuzumab (Herceptin) in HER2-positive early breast cancer. Breast. 2007;16:63
  83. Ewer MS, Lenihan DJ. Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground?. J Clin Oncol. 2008;26:1201–1203
  84. Zethelius B, Berglund L, Sundström J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med. 2008;358:2107–2116
  85. Perik PJ, De Vries EG, Boomsma F, et al. Use of natriuretic peptides for detecting cardiac dysfunction in long-term disease-free breast cancer survivors. Anticancer Res. 2005;25:3651–3657
  86. Jurcut R, Wildiers H, Ganame J, D’hooge J, Paridaens R, Voigt JU. Detection and monitoring of cardiotoxicity-what does modern cardiology offer?. Support Care Cancer. 2008;16:437–445
  87. Cawthon RM, Smith KR, O’Brien E, Sivatchenko A, Kerber RA. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet. 2003;361:393–395

PII: S1040-8428(10)00027-2

doi: 10.1016/j.critrevonc.2010.01.012

Critical Reviews in Oncology / Hematology
Volume 76, Issue 3 , Pages 186-195 , December 2010

Article Tools